These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 19996271)

  • 1. Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent O6-methylguanine-DNA methyltransferase.
    Gao Y; Fotovati A; Lee C; Wang M; Cote G; Guns E; Toyota B; Faury D; Jabado N; Dunn SE
    Mol Cancer Ther; 2009 Dec; 8(12):3276-84. PubMed ID: 19996271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
    Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
    Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
    Chen Z; Wei X; Shen L; Zhu H; Zheng X
    Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is the absolute value of O(6)-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide?
    Tanaka S; Akimoto J; Narita Y; Oka H; Tashiro T
    J Neurosurg; 2014 Oct; 121(4):818-26. PubMed ID: 25105699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.
    Banelli B; Carra E; Barbieri F; Würth R; Parodi F; Pattarozzi A; Carosio R; Forlani A; Allemanni G; Marubbi D; Florio T; Daga A; Romani M
    Cell Cycle; 2015; 14(21):3418-29. PubMed ID: 26566863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma.
    Tian T; Mingyi M; Qiu X; Qiu Y
    Oncotarget; 2016 Nov; 7(48):79584-79595. PubMed ID: 27792996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression.
    Tancredi A; Gusyatiner O; Bady P; Buri MC; Lomazzi R; Chiesi D; Messerer M; Hegi ME
    Cell Death Dis; 2022 Dec; 13(12):1037. PubMed ID: 36513631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The DNA repair protein ALKBH2 mediates temozolomide resistance in human glioblastoma cells.
    Johannessen TC; Prestegarden L; Grudic A; Hegi ME; Tysnes BB; Bjerkvig R
    Neuro Oncol; 2013 Mar; 15(3):269-78. PubMed ID: 23258843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication.
    Aghi M; Rabkin S; Martuza RL
    J Natl Cancer Inst; 2006 Jan; 98(1):38-50. PubMed ID: 16391370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1α stability and MGMT expression.
    Persano L; Pistollato F; Rampazzo E; Della Puppa A; Abbadi S; Frasson C; Volpin F; Indraccolo S; Scienza R; Basso G
    Cell Death Dis; 2012 Oct; 3(10):e412. PubMed ID: 23076220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide.
    Younis SG; Khedr RA; El-Shorbagy SH
    J Egypt Natl Canc Inst; 2016 Mar; 28(1):23-30. PubMed ID: 26682634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lnc-TALC promotes O
    Wu P; Cai J; Chen Q; Han B; Meng X; Li Y; Li Z; Wang R; Lin L; Duan C; Kang C; Jiang C
    Nat Commun; 2019 May; 10(1):2045. PubMed ID: 31053733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of MLH1 and PMS2 confers temozolomide resistance and is associated with recurrence of glioblastoma.
    Shinsato Y; Furukawa T; Yunoue S; Yonezawa H; Minami K; Nishizawa Y; Ikeda R; Kawahara K; Yamamoto M; Hirano H; Tokimura H; Arita K
    Oncotarget; 2013 Dec; 4(12):2261-70. PubMed ID: 24259277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression.
    Kohsaka S; Wang L; Yachi K; Mahabir R; Narita T; Itoh T; Tanino M; Kimura T; Nishihara H; Tanaka S
    Mol Cancer Ther; 2012 Jun; 11(6):1289-99. PubMed ID: 22532597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling.
    Pyko IV; Nakada M; Sabit H; Teng L; Furuyama N; Hayashi Y; Kawakami K; Minamoto T; Fedulau AS; Hamada J
    Carcinogenesis; 2013 Oct; 34(10):2206-17. PubMed ID: 23715499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MGMT-independent temozolomide resistance in pediatric glioblastoma cells associated with a PI3-kinase-mediated HOX/stem cell gene signature.
    Gaspar N; Marshall L; Perryman L; Bax DA; Little SE; Viana-Pereira M; Sharp SY; Vassal G; Pearson AD; Reis RM; Hargrave D; Workman P; Jones C
    Cancer Res; 2010 Nov; 70(22):9243-52. PubMed ID: 20935218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models.
    Middlemas DS; Stewart CF; Kirstein MN; Poquette C; Friedman HS; Houghton PJ; Brent TP
    Clin Cancer Res; 2000 Mar; 6(3):998-1007. PubMed ID: 10741727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.
    Hegi ME; Diserens AC; Godard S; Dietrich PY; Regli L; Ostermann S; Otten P; Van Melle G; de Tribolet N; Stupp R
    Clin Cancer Res; 2004 Mar; 10(6):1871-4. PubMed ID: 15041700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. O6-Methylguanine-DNA methyltransferase is a novel negative effector of invasion in glioblastoma multiforme.
    Chahal M; Abdulkarim B; Xu Y; Guiot MC; Easaw JC; Stifani N; Sabri S
    Mol Cancer Ther; 2012 Nov; 11(11):2440-50. PubMed ID: 22986464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
    Boccard SG; Marand SV; Geraci S; Pycroft L; Berger FR; Pelletier LA
    Oncotarget; 2015 Oct; 6(30):29456-68. PubMed ID: 26336131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.